KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) EBIT Margin (2016 - 2025)

Historic EBIT Margin for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to 109.95%.

  • TherapeuticsMD's EBIT Margin rose 973600.0% to 109.95% in Q3 2025 from the same period last year, while for Sep 2025 it was 61.8%, marking a year-over-year increase of 3564900.0%. This contributed to the annual value of 270.3% for FY2024, which is 3843100.0% up from last year.
  • TherapeuticsMD's EBIT Margin amounted to 109.95% in Q3 2025, which was up 973600.0% from 73.0% recorded in Q2 2025.
  • TherapeuticsMD's EBIT Margin's 5-year high stood at 104.95% during Q4 2024, with a 5-year trough of 4269.25% in Q2 2022.
  • Over the past 5 years, TherapeuticsMD's median EBIT Margin value was 221.63% (recorded in 2025), while the average stood at 971.35%.
  • In the last 5 years, TherapeuticsMD's EBIT Margin plummeted by -41163100bps in 2022 and then surged by 37035800bps in 2023.
  • TherapeuticsMD's EBIT Margin (Quarter) stood at 189.48% in 2021, then skyrocketed by 137bps to 70.65% in 2022, then tumbled by -554bps to 320.92% in 2023, then surged by 133bps to 104.95% in 2024, then plummeted by -205bps to 109.95% in 2025.
  • Its last three reported values are 109.95% in Q3 2025, 73.0% for Q2 2025, and 221.63% during Q1 2025.